Lexeo Therapeutics
Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.
97 employees · est. 2018 · New York, United States
RiboNova, Inc.
Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also have tRNA discovery.
7 employees · est. 2011 · Wynnewood, United States
RiboNova, Inc. is the older company (2018 vs 2011); Lexeo Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Lexeo Therapeutics | RiboNova, Inc. |
|---|---|---|
| Founded | ||
| Founded | 2018 | 2011 older |
| Headquarters | ||
| Headquarters | New York, United States | Wynnewood, United States |
| Employees | ||
| Employees | 97 larger | 7 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness, Life Sciences | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series Unknown |
| Total Funding | ||
| Total Funding | $280.00M | $25.00K |
| Funding Rounds | ||
| Funding Rounds | 4 | 2 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Genetic Medicine, Clinical-stage, Gene Therapy, Rare Diseases, Cardiovascular Diseases, Alzheimer's Disease, AAV-mediated Therapies, Weill Cornell Medicine, University Of California San Diego, New York City, Research Collaboration, Commercialization, Preclinical Pipeline, Innovation | Biopharmaceutical Company, Rare Diseases, Mitochondrial Disease, Treatment, Drug Discovery, Precision Medicine, TRNA, Genetic Diagnosis, DNA Sequencing, Ribonucleic Acid, Clinical Biomarkers, Therapeutic Targets, Translational Medicine, Phase-2 Ready Drug |
| Website | ||
| Website | lexeotx.com | ribonova.com |
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based biotechnology startup that is making waves in the field of genetic medicines. The company is on a mission to revolutionize healthcare by leveraging cutting-edge science to change the way diseases are treated. Its focus areas include cardiovascular and APOE...
About RiboNova, Inc.
RiboNova, Inc. is a biopharmaceutical company founded in 2011, with a primary focus on developing treatments for mitochondrial disease and other serious rare diseases. The company's flagship asset, R007, is a Phase-2 ready small molecule drug designed to address all forms of genetically-confirmed mi...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Lexeo Therapeutics and RiboNova, Inc. — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Lexeo Therapeutics and RiboNova, Inc. — by email.
Frequently Asked Questions
Compare Lexeo Therapeutics with someone else
Start typing a company name or domain.